Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.

ABSTRACT:

Background

Preapproval trials showed that messenger RNA (mRNA)-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the safety of the BNT162b2 mRNA vaccine with respect to a broad range of potential adverse events is needed.

Methods

We used data from the largest health care organization in Israel to evaluate the safety of the BNT162b2 mRNA vaccine. For each potential adverse event, in a population of persons with no previous diagnosis of that event, we individually matched vaccinated persons to unvaccinated persons according to sociodemographic and clinical variables. Risk ratios and risk differences at 42 days after vaccination were d

SUBMITTER: Barda N 

PROVIDER: S-EPMC8427535 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature